Published in J Acquir Immune Defic Syndr on July 01, 2009
Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS (2012) 2.65
Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis (2014) 2.65
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis (2015) 1.76
HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J (2011) 1.34
Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One (2013) 1.16
Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One (2012) 1.12
Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials. PLoS One (2013) 1.05
Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan. Pharmacoepidemiol Drug Saf (2014) 0.88
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. BMC Infect Dis (2011) 0.88
Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review. Infect Dis Ther (2015) 0.83
Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS Res Hum Retroviruses (2012) 0.81
Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems. Cholesterol (2010) 0.81
Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV. Adv Ther (2010) 0.80
Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee. Can J Infect Dis Med Microbiol (2011) 0.80
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia. PLoS One (2015) 0.78
Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART. Eur J Clin Microbiol Infect Dis (2016) 0.76
Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use. Infect Dis Ther (2015) 0.75
Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. Drugs (2016) 0.75
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One (2011) 0.75
Bone mineral density in people living with HIV: a narrative review of the literature. AIDS Res Ther (2017) 0.75
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med (2006) 8.35
Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med (2009) 7.82
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 7.31
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis (2010) 4.42
Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr (2002) 4.39
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis (2011) 3.58
Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis (2013) 3.17
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06
Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. JAMA (2012) 3.01
Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol (2005) 2.99
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS (2008) 2.92
Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr (2010) 2.85
Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med (2007) 2.79
Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr (2009) 2.77
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med (2003) 2.64
QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol (2003) 2.62
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr (2004) 2.55
Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis (2006) 2.49
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS (2004) 2.39
HIV and syphilis: when to perform a lumbar puncture. Sex Transm Dis (2007) 2.35
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS (2002) 2.29
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol (2013) 2.29
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS (2002) 2.28
Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis. Am J Respir Crit Care Med (2003) 2.22
Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann Intern Med (2003) 2.20
Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology (2009) 2.18
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
[Antiretroviral therapy of HIV infection: duration and reasons for changing the first therapeutic regimen in 518 patients]. Med Clin (Barc) (2006) 2.14
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr (2009) 2.14
Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine (2008) 2.13
Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr (2004) 2.11
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis (2011) 2.10
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Long-term effectiveness of infrared coagulation for the treatment of anal intraepithelial neoplasia grades 2 and 3 in HIV-infected men and women. AIDS (2013) 2.06
Transmission of HIV-1 from an obstetrician to a patient during a caesarean section. AIDS (2006) 2.06
Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med (2005) 2.04
Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides. PLoS Biol (2012) 2.03
[Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]. Enferm Infecc Microbiol Clin (2011) 2.03
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]. Enferm Infecc Microbiol Clin (2012) 2.02
[Community bacteremia ambulatory treated or identified after discharge from the emergency department]. Med Clin (Barc) (2007) 2.01
[Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. CoRIS cohort, 2011]. Enferm Infecc Microbiol Clin (2012) 2.01
Prevention of infective endocarditis: between progress in scientific knowledge and the lack of randomized trials. Rev Esp Cardiol (Engl Ed) (2012) 1.99
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS (2007) 1.98
[The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up]. Enferm Infecc Microbiol Clin (2011) 1.92
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther (2011) 1.90
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study. J Bone Miner Res (2013) 1.84
Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses (2008) 1.84
Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr (2012) 1.84
[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]. Enferm Infecc Microbiol Clin (2007) 1.83
Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med (2005) 1.83
Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care (2005) 1.80
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother (2009) 1.79
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis (2009) 1.79